# Nuvectis Pharma, Inc. > Alpha governed public record. Unknown, unavailable, and unpublished values are never inferred as zero. ## Record | Field | Value | | --- | --- | | Representation | alpha-profile-markdown-v4 | | Protocol | Alpha Governance Facts Protocol 0.1 | | Schema | alpha.governance.entity.public.v1 | | Record version | public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce | | Governance record representation | alpha-governance-record-v2 | | Canonical entity | alpha:company:49b893af-4724-463f-9428-d39ae6a409df | | Entity type | Company | | Canonical URL | https://registry.alpha.ac/companies/nuvectis-pharma-inc | | Publication | PUBLISHED | | Verification | source_reported | | Verification schema | alpha-verification-states-v1 | | Ownership | unclaimed | | Published claims | 20 | | Claims under review | 1 | | Evidence records | 7 | | Conflicts | 0 | | Conflicts in internal review | 0 | | Observed | 2026-10-27T16:21:18.627267+00:00 | | Last reviewed | 2026-10-27T16:21:18.627267+00:00 | ## Identity - Legal name: Nuvectis Pharma, Inc. - Display name: Nuvectis Pharma, Inc. ## Alpha Governance Record | Field | Value | | --- | --- | | Governance Record schema | alpha-governance-record-v2 | | Ontology | alpha-governance-ontology-v1 | | Record version | public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce | | As of | 2026-10-28T00:41:22.398267+00:00 | | Completeness | 0.409 | | Record Quality | 0.834 | | Directors | 4 | | Committees | 5 | | Governance events | 14 | | Entity class | public_company | ## Section coverage | Section | State | | --- | --- | | identity | PUBLISHED | | corporate_structure | NOT_REVIEWED | | board | PUBLISHED | | committees | PUBLISHED | | leadership | PUBLISHED | | ownership | NOT_REVIEWED | | financials | NOT_REVIEWED | | capital_structure | PUBLISHED | | compensation | NOT_REVIEWED | | governance | NOT_REVIEWED | | shareholder_governance | NOT_REVIEWED | | audit | NOT_REVIEWED | | legal | NOT_REVIEWED | | risk | NOT_REVIEWED | | cyber | NOT_REVIEWED | | ai_governance | NOT_REVIEWED | | agent_governance | RESTRICTED | | markets_external | NOT_REVIEWED | | events | PUBLISHED | | relationships | PUBLISHED | | assessments | PUBLISHED | | evidence | PUBLISHED | ## Board - James F. Oliviero, III: Director. Status: current. Independent: true. Since: 2021-01-01. Committees: Audit (chair); Audit · Chair; Compensation (member); Compensation (member). claim_id=alpha:claim:company:49b893af-4724-463f-9428-d39ae6a409df:leadership_role:5 - Kenneth Hoberman: Director. Status: current. Independent: true. Since: 2021-01-01. Committees: Audit (member); Audit; Compensation · Chair (member); Compensation (chair). claim_id=alpha:claim:company:49b893af-4724-463f-9428-d39ae6a409df:leadership_role:6 - Matthew Kaplan: Director. Status: current. Independent: true. Since: 2021-01-01. Committees: Audit (member); Audit; Compensation (member); Compensation (member). claim_id=alpha:claim:company:49b893af-4724-463f-9428-d39ae6a409df:leadership_role:7 - Ron Bentsur: Director. Status: current. Independent: false. Since: 2020-01-01. claim_id=alpha:claim:company:49b893af-4724-463f-9428-d39ae6a409df:leadership_role:8 ## Committees - Audit (audit). Chair: James F. Oliviero, III. Members: James F. Oliviero, III (chair, current); Kenneth Hoberman (member, current); Matthew Kaplan (member, current). committee_id=alpha:committee:nuvectis-pharma-inc:audit - Audit · Chair; Compensation (audit). Chair: NOT_PUBLISHED. Members: James F. Oliviero, III (member, current). committee_id=alpha:committee:nuvectis-pharma-inc:audit-chair-compensation - Audit; Compensation (audit). Chair: NOT_PUBLISHED. Members: Matthew Kaplan (member, current). committee_id=alpha:committee:nuvectis-pharma-inc:audit-compensation - Audit; Compensation · Chair (audit). Chair: NOT_PUBLISHED. Members: Kenneth Hoberman (member, current). committee_id=alpha:committee:nuvectis-pharma-inc:audit-compensation-chair - Compensation (compensation). Chair: Kenneth Hoberman. Members: Kenneth Hoberman (chair, current); James F. Oliviero, III (member, current); Matthew Kaplan (member, current). committee_id=alpha:committee:nuvectis-pharma-inc:compensation ## Executive leadership - Enrique Poradosu: Executive Vice President, Chief Scientific and Business Officer. Status: current. claim_id=alpha:claim:company:49b893af-4724-463f-9428-d39ae6a409df:leadership_role:9 - Michael Carson: Vice President of Finance. Status: current. claim_id=alpha:claim:company:49b893af-4724-463f-9428-d39ae6a409df:leadership_role:10 - Ron Bentsur: Chairman, Chief Executive Officer and President [CEO]. Status: current. claim_id=alpha:claim:company:49b893af-4724-463f-9428-d39ae6a409df:leadership_role:11 - Shay Shemesh: Executive Vice President, Chief Development and Operations Officer. Status: current. claim_id=alpha:claim:company:49b893af-4724-463f-9428-d39ae6a409df:leadership_role:12 ## Governance events - EXECUTIVE_APPOINTED: Enrique Poradosu executive of Nuvectis Pharma, Inc., effective 2026-02-11. Effective: 2026-02-11. Detected: 2026-10-27T16:21:18.627267+00:00. event_id=alpha:event:transition:ws64ktijncad - EXECUTIVE_APPOINTED: Michael Carson executive of Nuvectis Pharma, Inc., effective 2026-02-11. Effective: 2026-02-11. Detected: 2026-10-27T16:21:18.627267+00:00. event_id=alpha:event:transition:1al0e3oq7jzgm - CEO_CHANGED: Ron Bentsur executive of Nuvectis Pharma, Inc., effective 2026-02-11. Effective: 2026-02-11. Detected: 2026-10-27T16:21:18.627267+00:00. event_id=alpha:event:transition:ev4ass1wfm854 - EXECUTIVE_APPOINTED: Shay Shemesh executive of Nuvectis Pharma, Inc., effective 2026-02-11. Effective: 2026-02-11. Detected: 2026-10-27T16:21:18.627267+00:00. event_id=alpha:event:transition:loixle1nyrlu6 - DIRECTOR_APPOINTED: James F. Oliviero, III seat on Nuvectis Pharma, Inc., effective 2021-01-01. Effective: 2021-01-01. Detected: 2026-10-27T16:21:18.627267+00:00. event_id=alpha:event:transition:15vxrwebxirfq - DIRECTOR_APPOINTED: Kenneth Hoberman seat on Nuvectis Pharma, Inc., effective 2021-01-01. Effective: 2021-01-01. Detected: 2026-10-27T16:21:18.627267+00:00. event_id=alpha:event:transition:bwogef1ykx - DIRECTOR_APPOINTED: Matthew Kaplan seat on Nuvectis Pharma, Inc., effective 2021-01-01. Effective: 2021-01-01. Detected: 2026-10-27T16:21:18.627267+00:00. event_id=alpha:event:transition:c57qvw66psxw - COMMITTEE_CREATED: Audit · Chair; Compensation committee of Nuvectis Pharma, Inc., effective 2021-01-01. Effective: 2021-01-01. Detected: 2026-10-27T16:21:18.627267+00:00. event_id=alpha:event:transition:e5p3suuor1p2 - COMMITTEE_MEMBER_ADDED: James F. Oliviero, III member of Audit · Chair; Compensation, effective 2021-01-01. Effective: 2021-01-01. Detected: 2026-10-27T16:21:18.627267+00:00. event_id=alpha:event:transition:1isfmfqx5ymp - COMMITTEE_CREATED: Audit; Compensation committee of Nuvectis Pharma, Inc., effective 2021-01-01. Effective: 2021-01-01. Detected: 2026-10-27T16:21:18.627267+00:00. event_id=alpha:event:transition:rm618k1t7aot8 - COMMITTEE_MEMBER_ADDED: Matthew Kaplan member of Audit; Compensation, effective 2021-01-01. Effective: 2021-01-01. Detected: 2026-10-27T16:21:18.627267+00:00. event_id=alpha:event:transition:ngk66hlxjqfz - COMMITTEE_CREATED: Audit; Compensation · Chair committee of Nuvectis Pharma, Inc., effective 2021-01-01. Effective: 2021-01-01. Detected: 2026-10-27T16:21:18.627267+00:00. event_id=alpha:event:transition:yamyo91ro5lol - COMMITTEE_MEMBER_ADDED: Kenneth Hoberman member of Audit; Compensation · Chair, effective 2021-01-01. Effective: 2021-01-01. Detected: 2026-10-27T16:21:18.627267+00:00. event_id=alpha:event:transition:kxi03ajza3qm - DIRECTOR_APPOINTED: Ron Bentsur seat on Nuvectis Pharma, Inc., effective 2020-01-01. Effective: 2020-01-01. Detected: 2026-10-27T16:21:18.627267+00:00. event_id=alpha:event:transition:qk8p0q122f5uq ## Scoped resources - `alpha://company/nuvectis-pharma-inc` (contract): https://registry.alpha.ac/api/public/companies/nuvectis-pharma-inc?format=record - `alpha://company/nuvectis-pharma-inc/identity` (contract): https://registry.alpha.ac/api/public/companies/nuvectis-pharma-inc?format=record§ion=identity - `alpha://company/nuvectis-pharma-inc/corporate-structure` (contract): https://registry.alpha.ac/api/public/companies/nuvectis-pharma-inc?format=record§ion=corporate-structure - `alpha://company/nuvectis-pharma-inc/board` (contract): https://registry.alpha.ac/api/public/companies/nuvectis-pharma-inc?format=record§ion=board - `alpha://company/nuvectis-pharma-inc/committees` (contract): https://registry.alpha.ac/api/public/companies/nuvectis-pharma-inc?format=record§ion=committees - `alpha://company/nuvectis-pharma-inc/leadership` (contract): https://registry.alpha.ac/api/public/companies/nuvectis-pharma-inc?format=record§ion=leadership - `alpha://company/nuvectis-pharma-inc/ownership` (contract): https://registry.alpha.ac/api/public/companies/nuvectis-pharma-inc?format=record§ion=ownership - `alpha://company/nuvectis-pharma-inc/financials` (contract): https://registry.alpha.ac/api/public/companies/nuvectis-pharma-inc?format=record§ion=financials - `alpha://company/nuvectis-pharma-inc/capital-structure` (contract): https://registry.alpha.ac/api/public/companies/nuvectis-pharma-inc?format=record§ion=capital-structure - `alpha://company/nuvectis-pharma-inc/compensation` (contract): https://registry.alpha.ac/api/public/companies/nuvectis-pharma-inc?format=record§ion=compensation - `alpha://company/nuvectis-pharma-inc/governance` (contract): https://registry.alpha.ac/api/public/companies/nuvectis-pharma-inc?format=record§ion=governance - `alpha://company/nuvectis-pharma-inc/shareholder-governance` (contract): https://registry.alpha.ac/api/public/companies/nuvectis-pharma-inc?format=record§ion=shareholder-governance - `alpha://company/nuvectis-pharma-inc/audit` (contract): https://registry.alpha.ac/api/public/companies/nuvectis-pharma-inc?format=record§ion=audit - `alpha://company/nuvectis-pharma-inc/legal` (contract): https://registry.alpha.ac/api/public/companies/nuvectis-pharma-inc?format=record§ion=legal - `alpha://company/nuvectis-pharma-inc/risk` (contract): https://registry.alpha.ac/api/public/companies/nuvectis-pharma-inc?format=record§ion=risk - `alpha://company/nuvectis-pharma-inc/cyber` (contract): https://registry.alpha.ac/api/public/companies/nuvectis-pharma-inc?format=record§ion=cyber - `alpha://company/nuvectis-pharma-inc/ai-governance` (contract): https://registry.alpha.ac/api/public/companies/nuvectis-pharma-inc?format=record§ion=ai-governance - `alpha://company/nuvectis-pharma-inc/agents` (contract): https://registry.alpha.ac/api/public/companies/nuvectis-pharma-inc?format=record§ion=agents - `alpha://company/nuvectis-pharma-inc/ecosystem` (contract): https://registry.alpha.ac/api/public/companies/nuvectis-pharma-inc?format=record§ion=ecosystem - `alpha://company/nuvectis-pharma-inc/events` (contract): https://registry.alpha.ac/api/public/companies/nuvectis-pharma-inc?format=record§ion=events - `alpha://company/nuvectis-pharma-inc/relationships` (contract): https://registry.alpha.ac/api/public/companies/nuvectis-pharma-inc?format=record§ion=relationships - `alpha://company/nuvectis-pharma-inc/assessments` (contract): https://registry.alpha.ac/api/public/companies/nuvectis-pharma-inc?format=record§ion=assessments - `alpha://company/nuvectis-pharma-inc/evidence` (contract): https://registry.alpha.ac/api/public/companies/nuvectis-pharma-inc?format=record§ion=evidence ## Role modules - NOT_ASSERTED ## Attention - NO_RECORDS_FOUND ## Committee data - Claim alpha:claim:company:49b893af-4724-463f-9428-d39ae6a409df:committee_appointment:14: `{"kind":"committee_appointment","original_name":"Audit","category":"audit","role":"chair","person":{"alpha_id":"alpha:person:james-f-oliviero-iii","name":"James F. Oliviero, III"},"source_id":"board_seats"}` - Claim alpha:claim:company:49b893af-4724-463f-9428-d39ae6a409df:committee_appointment:15: `{"kind":"committee_appointment","original_name":"Audit","category":"audit","role":"member","person":{"alpha_id":"alpha:person:kenneth-hoberman","name":"Kenneth Hoberman"},"source_id":"board_seats"}` - Claim alpha:claim:company:49b893af-4724-463f-9428-d39ae6a409df:committee_appointment:16: `{"kind":"committee_appointment","original_name":"Audit","category":"audit","role":"member","person":{"alpha_id":"alpha:person:matthew-kaplan","name":"Matthew Kaplan"},"source_id":"board_seats"}` - Claim alpha:claim:company:49b893af-4724-463f-9428-d39ae6a409df:committee_appointment:18: `{"kind":"committee_appointment","original_name":"Compensation","category":"compensation","role":"chair","person":{"alpha_id":"alpha:person:kenneth-hoberman","name":"Kenneth Hoberman"},"source_id":"board_seats"}` - Claim alpha:claim:company:49b893af-4724-463f-9428-d39ae6a409df:committee_appointment:19: `{"kind":"committee_appointment","original_name":"Compensation","category":"compensation","role":"member","person":{"alpha_id":"alpha:person:james-f-oliviero-iii","name":"James F. Oliviero, III"},"source_id":"board_seats"}` - Claim alpha:claim:company:49b893af-4724-463f-9428-d39ae6a409df:committee_appointment:20: `{"kind":"committee_appointment","original_name":"Compensation","category":"compensation","role":"member","person":{"alpha_id":"alpha:person:matthew-kaplan","name":"Matthew Kaplan"},"source_id":"board_seats"}` ## Leadership - James F. Oliviero, III: Director, Audit · Chair; Compensation. Claim: alpha:claim:company:49b893af-4724-463f-9428-d39ae6a409df:leadership_role:5. Valid from: 2021-01-01. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:f055be2e5475cf6055986058302903670547a0c5f013721891fb4609e2349f72. - Kenneth Hoberman: Director, Audit; Compensation · Chair. Claim: alpha:claim:company:49b893af-4724-463f-9428-d39ae6a409df:leadership_role:6. Valid from: 2021-01-01. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:f055be2e5475cf6055986058302903670547a0c5f013721891fb4609e2349f72. - Matthew Kaplan: Director, Audit; Compensation. Claim: alpha:claim:company:49b893af-4724-463f-9428-d39ae6a409df:leadership_role:7. Valid from: 2021-01-01. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:f055be2e5475cf6055986058302903670547a0c5f013721891fb4609e2349f72. - Ron Bentsur: Director. Claim: alpha:claim:company:49b893af-4724-463f-9428-d39ae6a409df:leadership_role:8. Valid from: 2020-01-01. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:f055be2e5475cf6055986058302903670547a0c5f013721891fb4609e2349f72. - Enrique Poradosu: Executive Vice President, Chief Scientific and Business Officer. Claim: alpha:claim:company:49b893af-4724-463f-9428-d39ae6a409df:leadership_role:9. Valid from: 2026-02-11. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:14f9951817e5cf29fcc1637d0a99b1c401d54353a321007c28927d94f4ffcaee. - Michael Carson: Vice President of Finance. Claim: alpha:claim:company:49b893af-4724-463f-9428-d39ae6a409df:leadership_role:10. Valid from: 2026-02-11. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:ac03bb87cfa1544d66ce74cfa09018e7cbbb33e4f4e67f46566a9843c18029af. - Ron Bentsur: Chairman, Chief Executive Officer and President. Claim: alpha:claim:company:49b893af-4724-463f-9428-d39ae6a409df:leadership_role:11. Valid from: 2026-02-11. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:7b8808041a29c36944228fbfe3023401a30f29f46cd969ff03cf96ffa46103f5. - Shay Shemesh: Executive Vice President, Chief Development and Operations Officer. Claim: alpha:claim:company:49b893af-4724-463f-9428-d39ae6a409df:leadership_role:12. Valid from: 2026-02-11. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:41d33a48e2eb35d831f43918e75a33a65e73aa42e737ae63991d1fec977d0f9f. ## Roles - PUBLISHED ## Governance - NOT_ASSERTED ## Board committees - Audit: Chair James F. Oliviero, III; Members James F. Oliviero, III (Chair); Kenneth Hoberman; Matthew Kaplan. Claim: alpha:claim:company:49b893af-4724-463f-9428-d39ae6a409df:committee_record:13. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:660557a74dc93cbe0b9bd6d746012574372d9a0de76b61725f7a3d626ddb06d0. - Compensation: Chair Kenneth Hoberman; Members Kenneth Hoberman (Chair); James F. Oliviero, III; Matthew Kaplan. Claim: alpha:claim:company:49b893af-4724-463f-9428-d39ae6a409df:committee_record:17. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:660557a74dc93cbe0b9bd6d746012574372d9a0de76b61725f7a3d626ddb06d0. ## Financials - NOT_ASSERTED ## Workforce - NOT_ASSERTED ## Market and index context - PUBLISHED ## Legal Name - Nuvectis Pharma, Inc.. Claim: alpha:claim:company:49b893af-4724-463f-9428-d39ae6a409df:legal_name:1. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:87840677727eef6b5a9083630eaf02472cfba344ba2bed632208beb31a073a0d. ## Entity Status - Public listing published. Claim: alpha:claim:company:49b893af-4724-463f-9428-d39ae6a409df:entity_status:3. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:87840677727eef6b5a9083630eaf02472cfba344ba2bed632208beb31a073a0d. ## Published Fact - US. Claim: alpha:claim:company:49b893af-4724-463f-9428-d39ae6a409df:published_fact:4. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:87840677727eef6b5a9083630eaf02472cfba344ba2bed632208beb31a073a0d. ## Committee Appointment - James F. Oliviero, III: chair, Audit. Claim: alpha:claim:company:49b893af-4724-463f-9428-d39ae6a409df:committee_appointment:14. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:660557a74dc93cbe0b9bd6d746012574372d9a0de76b61725f7a3d626ddb06d0. - Kenneth Hoberman: member, Audit. Claim: alpha:claim:company:49b893af-4724-463f-9428-d39ae6a409df:committee_appointment:15. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:660557a74dc93cbe0b9bd6d746012574372d9a0de76b61725f7a3d626ddb06d0. - Matthew Kaplan: member, Audit. Claim: alpha:claim:company:49b893af-4724-463f-9428-d39ae6a409df:committee_appointment:16. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:660557a74dc93cbe0b9bd6d746012574372d9a0de76b61725f7a3d626ddb06d0. - Kenneth Hoberman: chair, Compensation. Claim: alpha:claim:company:49b893af-4724-463f-9428-d39ae6a409df:committee_appointment:18. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:660557a74dc93cbe0b9bd6d746012574372d9a0de76b61725f7a3d626ddb06d0. - James F. Oliviero, III: member, Compensation. Claim: alpha:claim:company:49b893af-4724-463f-9428-d39ae6a409df:committee_appointment:19. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:660557a74dc93cbe0b9bd6d746012574372d9a0de76b61725f7a3d626ddb06d0. - Matthew Kaplan: member, Compensation. Claim: alpha:claim:company:49b893af-4724-463f-9428-d39ae6a409df:committee_appointment:20. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:660557a74dc93cbe0b9bd6d746012574372d9a0de76b61725f7a3d626ddb06d0. ## Security Listing - NVCT (NASDAQ). Claim: alpha:claim:company:49b893af-4724-463f-9428-d39ae6a409df:security_listing:21. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:87840677727eef6b5a9083630eaf02472cfba344ba2bed632208beb31a073a0d. ## Coverage states | Field | Value | | --- | --- | | Identity | PUBLISHED | | Business | PUBLISHED | | Leadership | PUBLISHED | | Board and committees | PUBLISHED | | Governance | NOT_ASSERTED | | Financials | NOT_ASSERTED | | Workforce | NOT_ASSERTED | | Ownership | NOT_ASSERTED | | Ratings | NOT_PUBLISHED | | Market and index context | PUBLISHED | ## Public sources - alpha:projection-evidence:87840677727eef6b5a9083630eaf02472cfba344ba2bed632208beb31a073a0d: [Alpha canonical company public projection](https://www.alpha.ac/api/public/companies/nuvectis-pharma-inc). - alpha:projection-evidence:document:f055be2e5475cf6055986058302903670547a0c5f013721891fb4609e2349f72: [Nuvectis Pharma, Inc. DEF 14A 2025-04-28](https://www.sec.gov/Archives/edgar/data/1875558/000110465925040225/tm252541-4_def14a.htm). - alpha:projection-evidence:document:14f9951817e5cf29fcc1637d0a99b1c401d54353a321007c28927d94f4ffcaee: [NVCT 10-K executive officers](https://www.sec.gov/Archives/edgar/data/1875558/000110465926013044/tmb-20251231x10k.htm). - alpha:projection-evidence:document:ac03bb87cfa1544d66ce74cfa09018e7cbbb33e4f4e67f46566a9843c18029af: [NVCT 10-K executive officers](https://www.sec.gov/Archives/edgar/data/1875558/000110465926013044/tmb-20251231x10k.htm). - alpha:projection-evidence:document:7b8808041a29c36944228fbfe3023401a30f29f46cd969ff03cf96ffa46103f5: [NVCT 10-K executive officers](https://www.sec.gov/Archives/edgar/data/1875558/000110465926013044/tmb-20251231x10k.htm). - alpha:projection-evidence:document:41d33a48e2eb35d831f43918e75a33a65e73aa42e737ae63991d1fec977d0f9f: [NVCT 10-K executive officers](https://www.sec.gov/Archives/edgar/data/1875558/000110465926013044/tmb-20251231x10k.htm). - alpha:projection-evidence:660557a74dc93cbe0b9bd6d746012574372d9a0de76b61725f7a3d626ddb06d0: [Audit](https://www.sec.gov/Archives/edgar/data/1875558/000110465925040225/tm252541-4_def14a.htm). ## Rights | Field | Value | | --- | --- | | public_retrieval | allowed | | agent_retrieval | allowed | | redistribution | not_granted | | model_training | not_granted | | commercial_use | not_specified | | relationship_pathfinding | not_granted | | direct_contact | not_granted | ## Limitations - Absence of a leadership role, committee, or disclosure is not evidence that it does not exist. - Only explicitly published canonical company identity and current confirmed public roles are included. - Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist. - Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights. - This Company Profile is an identity and evidence record, not an Alpha rating. ## Alternate representations - [Canonical profile](https://registry.alpha.ac/companies/nuvectis-pharma-inc) - [Public Markdown](https://registry.alpha.ac/companies/nuvectis-pharma-inc.md) - [Public JSON](https://registry.alpha.ac/api/public/companies/nuvectis-pharma-inc?format=record) - [JSON-LD](https://registry.alpha.ac/api/public/companies/nuvectis-pharma-inc?format=jsonld) - MCP resource: `alpha://companies/nuvectis-pharma-inc` at https://mcp.alpha.ac/mcp ## Connected governance records Only explicitly published, rights-cleared records. Missing records do not establish absence, safety, or complete coverage. ## Critical-risk oversight Snapshot as of 2026-10-28T00:41:21.997908+00:00; recorded 2026-10-28T00:41:21.997908+00:00. Every published assignment for this snapshot is listed. Only explicitly reviewed, rights-cleared assignments in effect on the as-of date, in the company's own wording. An assignment shows where oversight is placed, not whether it is effective. Missing records do not establish absence.